Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) by Atzpodien, J et al.
Adjuvant treatment with interleukin-2- and interferon-alpha2a-
based chemoimmunotherapy in renal cell carcinoma post tumour
nephrectomy: Results of a prospectively randomised Trial of the
German Cooperative Renal Carcinoma Chemoimmunotherapy
Group (DGCIN)
J Atzpodien*,1,2, E Schmitt
3, U Gertenbach
4, P Fornara
5, H Heynemann
5, A Maskow
6, M Ecke
7,H HW o ¨ltjen
8,
H Jentsch
9, W Wieland
10, T Wandert
2 and M Reitz
2, DGCIN – German Cooperative Renal Carcinoma
Chemo-Immunotherapy Trials Group
1Fachklinik Hornheide an der Universita ¨t Mu ¨nster, Internistische Onkologie, Dorbaumstr. 300, 48157 Mu ¨nster, Germany;
2Europa ¨isches Institut fu ¨r
Tumor Immunologie und Pra ¨vention, Gotenstr. 152, 53175 Bonn, Germany;
3Kreiskrankenhaus Aschersleben, Urologische Klinik, Eislebender Str. 7a,
06449 Aschersleben, Germany;
4Allgemeines Krankenhaus der Stadt Hagen, Urologische Klinik, Gru ¨nstr. 35, 58095 Hagen, Germany;
5Klinikum der
Martin-Luther-Universita ¨t, Urologische Klinik, Ernst-Grube-Str. 40, 06120 Halle a.d. Saale, Germany;
6Universita ¨tsklinikum Leipzig, Klinik und Poliklinik fu ¨r
Urologie, Liebigstr. 21, 04103 Leipzig, Germany;
7Sta ¨dtisches Klinikum Magdeburg, Urologie, Birkenallee 34, 39002 Magdeburg, Germany;
8Klinikum
Minden, Ha ¨matologie/Onkologie, Portastr. 7-9, 32423 Minden, Germany;
9Klinikum Ernst-von Bergmann, Klinik fu ¨r Urologie, Charlottenstr. 72, 14467
Potsdam, Germany;
10Caritas Krankenhaus St Josef, Urologie, Landshuterstr. 65, 93053 Regensburg, Germany
We conducted a prospectively randomised clinical trial to investigate the role of adjuvant outpatient immunochemotherapy
administered postoperatively in high-risk patients with renal cell carcinoma. In total, 203 renal carcinoma patients’ status post radical
tumour nephrectomy were stratified into three risk groups: patients with tumour extending into renal vein/vena cava or invading
beyond Gerota’s fascia (pT3b/c pN0 or pT4pN0), patients with locoregional lymph node infiltration (pNþ), and patients after
complete resection of tumour relapse or solitary metastasis (R0). Patients were randomised to undergo either (A) 8 weeks of
outpatient subcutaneous interleukin-2 (sc-rIL-2), subcutaneous interferon-alpha2a (sc-rIFN-a2a), and intravenous 5-fluorouracil (iv-5-
FU) according to the standard Atzpodien regimen (Atzpodien et al, 2004) or (B) observation. Two-, 5-, and 8-year survival rates were
81, 58, and 58% in the treatment arm, and 91, 76, and 66% in the observation arm (log rank P¼0.0278), with a median follow-up of
4.3 years. Two, 5-, and 8-year relapse-free survival rates were calculated at 54, 42, and 39% in the treatment arm, and at 62, 49, and
49% in the observation arm (log rank P¼0.2398). Stage-adapted subanalyses revealed no survival advantages of treatment over
observation, as well. Our results established that there was no relapse-free survival benefit and the overall survival was inferior with an
adjuvant 8-week-outpatient sc-rIL-2/sc-rIFN-a2a/iv-5-FU-based immunochemotherapy compared to observation in high-risk renal
cell carcinoma patients following radical tumour nephrectomy.
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During the last decades, renal cell cancer has been increasing
in incidence in North America and Europe, with approxi-
mately one-third having metastatic disease at the time of
diagnosis. Patients with locally advanced renal cell carcinoma
are at high risk of recurrence, since relapse rates range from
50 to 85% depending on tumour (T) stage and nodal (N) status,
and reach close to 100% in recurrent disease patients who
have undergone R0 resection (Fleischmann et al, 1997; Messing
et al, 2003).
Until now, no adjuvant treatment including radiation, che-
motherapy, or immunotherapy of locally advanced renal cell
carcinoma has shown satisfactory results (Clark et al, 2003).
Promising results in the therapy of stage IV metastatic renal
cell carcinoma were reported using interleukin-2 (rIL-2) given
intravenously or subcutaneously as outpatient therapy alone
or in combination with interferon-a (rINF-a) yielding objective
response rates between 19 and 31% (Sleijfer et al, 1992;
Rosenberg et al, 1994; Atzpodien et al, 1995). Hereby, cytokine
outpatient therapy regimens (Atzpodien et al, 1995) showed
highly reduced systemic toxicities as compared to i.v. bolus
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sinfusions. The combination of subcutaneous cytokines with the
chemotherapeutic i.v. 5-fluorouracil (5-FU) further enhanced
antineoplastic activity achieving objective response rates
between 18 and 39% (Lopez-Ha ¨nninen et al, 1996; Dutcher et al,
2000; Atzpodien et al, 2001, 2004). Based on its efficacy in
metastatic renal cell carcinoma, we hypothesized that outpatient
sc-rIL-2/sc-rIFN-a2a/iv-5-FU-based immunochemotherapy accor-
ding to the standard Atzpodien regimen (Atzpodien et al,
2004) might extend progression-free and/or overall survival of
high-risk renal cell carcinoma patients in the postsurgical
adjuvant setting.
We, therefore, performed a prospective randomized clinical
study to compare the efficacy of sc-rIL-2/sc-rIFN-a2a/iv-5-FU vs
observation as an adjuvant approach in high-risk renal carcinoma
patients.
PATIENTS AND METHODS
Patients
Between October 1993 and February 2002, 203 high-risk patients
with resected renal cell carcinoma were stratified into three risk
groups: (1) patients with tumour extending into renal vein/vena
cava or invading beyond Gerota’s fascia (pT3b/c pN0 or pT4pN0;
n¼77), (2) patients with locoregional lymph node infiltra-
tion (pNþ, n¼36), and (3) patients after complete resection of
tumour relapse or solitary metastasis (pR0; n¼90); sponta-
neous 5-year systemic survival rates were 84, 70, and 71% in
pT3b/c pN0 or pT4pN0 patients, pNþ patients, and R0 patients,
respectively. Systemic pretreatment included, chemotherapy
(n¼1), immunotherapy (n¼10), and naturopathic therapy
(n¼1) (Table 1).
Criteria for entry into the study were: histologically confirmed
renal cell carcinoma (pT3b/c pN0 or pT4pN0; pNþ; R0), age
between 18 and 80 years; white blood cell count X3500ml
 1;
platelet count X100.000ml
 1; hematocrit X30%; serum bilirubin
p1.25, and creatinine p1.5 of the upper normal limit; Karnofsky
performance status X80%; no evidence of congestive heart failure,
no severe coronary artery disease, no cardiac arrhythmias, no
clinically symptomatic CNS disease or seizure disorders, no human
immunodeficiency virus infection, no evidence of chronic active
hepatitis, no concomitant corticosteroid therapy. In all patients
treated, no chemotherapy or immunmodulatory treatment had
been performed during the previous 4 weeks. Also, pregnant and
lactating women were excluded.
This study was approved by the institutional review board of the
Medizinische Hochschule Hannover. Upon written receipt of
patient prestudy evaluation, randomisation was performed; 135
patients were assigned to arm A, and 68 patients were assigend
to arm B.
Regimens
Patients randomised to adjuvant therapy (arm A) received one 8-
week treatment cycle of sc rIFN-a2a (Roferon
s, Hoffmann-La
Roche; Grenzach-Wyhlen, Germany) (5 10
6IUm
 2, day 1, weeks
1þ4; days 1, 3, 5, weeks 2þ3; 10 10
6IUm
 2, days 1, 3, 5, weeks
5–8), sc rIL-2 (Proleukin
s, Chiron, Emeryville, CA, USA)
(10 10
6IUm
 2, twice daily days 3–5, weeks 1þ4;
5 10
6IUm
 2, days 1, 3, 5, weeks 2 þ 3) and iv 5-FU
(1000mgm
 2, day 1, weeks 5–8). Patients at an age of 60 years
and older received a 20% dose reduction of sc IL-2 to avoid toxic
complications. Concomitant medication was given as needed to
control adverse effects of immunochemotherapy. Patients rando-
mised to undergo observation (arm B/control) received no
adjuvant therapy. In the event of relapse, all patients were offered
individual care outside the present study.
Assessment of survival
Survival was measured from start of therapy to date of death or to
the last known date to be alive. In case of progression upon first re-
evaluation after 8 weeks, relapse-free survival was calculated at 0
months. All patients had to be followed up for survival for at least 2
years as cutoff.
Statistical analysis
The statistical end points in our analysis were (1) relapse-free
survival (primary end point) and, (2) overall survival of patients.
The probability of relapse-free survival and overall survival
was plotted over time according to the method of Kaplan and
Meier (1958).
The potential 2-year –relapse-free survival rates were hypo-
thesised to show a 20% advantage of Arm A over Arm B (90 vs
70%). Using an a of 0.05 (one-sided), a sample size of 59
patients plus 20% potential drop outs per arm was needed to
have 80% power to statistically establish the assumed difference
in relapse-free survivals. The present 2:1 (treatment vs obser-
vation) randomisation was capable of meeting these statistical
end points.
Statistical significance was assessed using the log rank test. For
statistical analysis, the SPSS software for Windows (SPSS, Inc.,
Chicago, IL, USA) was applied.
Table 1 Patients characteristics and pretreatment
Treatment
Characteristics Arm A
a (n) Arm B
a (n) All patients (n)
Entered 135 68 203
Age (years)
Median 59 60 59
Range 31–77 38–77 31–77
Sex
Male 97 54 151
Female 38 14 52
Radical nephrectomy 135 68 203
Stratum
pT3b/c pN0 or T4pN0 50 27 77
pN+ 28 8 36
R0 57 33 90
Local 9 4 13
Lymph nodes 5 5 10
Organ metastases 37 22 59
Site unknown 6 2 8
Histological subtype
Clear cell 84 41 125
Granular 3 2 5
Sarkomatoid 2 1 3
Papillary 1 1 2
Mixed 22 8 30
Unknown 23 15 38
Systemic pretreatment
Chemotherapy 0 1 1
Immunotherapy
b 46 1 0
Naturopathic therapy 1 0 1
Unknown 6 0 6
aArm A (8 weeks of sc-rIL-2/sc-rIFN-a /iv 5-FU); Arm B (observation).
bIncluding IL-2/
IFN-a2, IL-2/Vaccine, and Vaccine. sc-rIL-2¼subcutaneous interleukin-2; sc-rIFN-
a2¼subcutaneous interferon-alpha2a, and iv-5-FU¼intravenous 5-fluorouracil.
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In total, 203 stratified renal carcinoma patients were prospectively
randomised to undergo either an 8-week treatment with sc rIL-2,
sc rIFN-a2a, and iv 5-FU (arm A, n¼135 patients) or to undergo
observation (arm B, n¼68 patients).
Overall survival
After a median follow-up of 4.3 years (range, 0.2–9.7 years),
82 patients (61%) in arm A (sc-rIL-2/sc-rIFN-a2a/iv-5-FU)
and 51 patients (75%) in arm B (observation) continued to be
alive. No therapy-induced toxic deaths occurred. Two-, 5-, and
8-year survival probabilities were 81, 58, and 58% on the treat-
ment arm, and 91, 76, and 66% on the observation arm
(Figure 1). Overall survival was significantly decreased (log rank
P¼0.0278) after treatment with immunochemotherapy (range,
0.2–8.4 years), when compared with the control (range, 0.3–9.7
years) (Figure 1).
Stage-related (pT3b/c pN0 or pT4pN0, pNþ, and R0) analysis
revealed no survival advantages of treatment over observation in
patient subgroups.
Relapse-free survival
A total of 77 patients (57%) in arm A (sc-rIL-2/sc-rIFN-a2a/iv-5-
FU) and 34 patients (50%) in arm B (observation) exhibited
tumour progression at last follow-up. Two, 5-, and 8-year relapse-
free survival probabilities were calculated at 54, 42, and 39% on the
treatment arm, with a median relapse-free survival of 2.75 years
(range, 0–8.2 years), and at 62, 49, and 49% on the observation
arm, with a median relapse-free survival of 4.25 years (range, 0–
9.7 years) (log rank P¼0.2398)(Figure 2). Thus, the statistical
hypotheses could not be established.
Within the three stratification groups (pT3b/c pN0 or pT4pN0,
pNþ, and R0), median relapse-free survival did not differ
significantly between arm A (sc-rIL-2/sc-rIFN-a2a/iv-5-FU) and
arm B (observation).
DISCUSSION
In this prospectively randomised trial, we reported the results of
203 tumour-free renal cell carcinoma patients after surgery of
locally advanced or distant metastatic disease who underwent an
adjuvant treatment with sc-rIL-2/sc-rIFN-a2a/iv-5-FU (arm A) or
underwent observation (arm B).
We demonstrated that high-risk renal cell carcinoma patients
did not benefit from an eight-week postoperative adjuvant
immunochemotherapy, both with respect to relapse-free survival
and with respect to overall survival. Thus, the primary relapse-free
survival end point of the current trial was not reached.
The lack of sc-rIL-2/sc-rIFN-a2a/iv-5-FU-related survival benefit
in the adjuvant renal carcinoma therapy was disappointing,
particularly when compared to the established efficacy in
metastatic renal cell carcinoma patients (Lopez-Ha ¨nninen et al,
1996; Elias et al, 1999; Atzpodien et al, 2001, 2004).
However, recent studies employing a-IFN-based therapy in the
adjuvant setting for renal cell carcinoma patients also did not
result in significant improvement regarding relapse-free survival
and overall survival (Pizzocaro et al, 2001; Messing et al, 2003).
In studies of Pizzocaro et al (2001), an adjuvant treatment with
IFN-alfa2b demonstrated a decrease in relapse rates in 26 patients
with extensive nodal disease (pN2/pN3), but an increase in
recurrence rates in node negative renal carcinoma patients.
Using tumour vaccination protocols with no interleukin-2 or a-
interferon, Repmann et al (2003) and Jocham et al (2004) were the
first investigators reporting positive adjuvant treatment results in
locally advanced renal cell carcinoma.
Overall, the present prospectively randomised clinical trial
reported here established that adjuvant 8-week outpatient sc rIL-2/
sc rIFN-a2a/iv 5-FU-based immunochemotherapy was inferior to
observation when administrated to high-risk patients with resected
renal cell carcinoma. It should be noted, though, that patients did
not benefit from therapy, but indeed may have been harmed. This
could be with toxicity, however, in the current trial toxicity was not
systematically studied; this should also be subject of future trials.
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